Lopinavir

規格

192725-17-0CAS番号

844-598-9EC番号

(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamideIUPAC名

C37H48N4O5化学式

628.8 g/mol分子量

Lopinavir; 192725-17-0; ABT-378; Aluviran; Koletra; A 157378.0; A-157378.0; Lopinavirum; DTXSID8046456; CHEBI:31781; A-157378-0; ABT378; Lopinavir, (s-(2s,4s,5s))-; (alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide; 2494G1JF75; (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; DTXCID6026456; (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; 1(2H)-Pyrimidineacetamide, N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphaS)-; (2S)-N-((2S,4S,5S)-5-((2-(2,6-dimethylphenoxy)acetyl)amino)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; (alphaS)-Tetrahydro-N-[(alphaS)-alpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[2-(2,6-xylyloxy)acetamido]butyl]phenethyl]-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide; N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide; RefChem:5960; ABT-378/r; A157378.0; J05AE06; ABT 378; (S)-N-((2S,4S,5S)-5-(2-(2,6-dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; RS-346; LPV; (alphaS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; A 157378; MFCD22628840; N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE; NCGC00164576-02; C37H48N4O5; (2S)-N-[(1S,3S,4S)-1-benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide; SMR002529581; CAS-192725-17-0; MFCD22373646; Lopinavir-; Lopinavir?; Lopinavir RS; Lopinavir CRS; UNII-2494G1JF75; HSDB 8138; 1mui; 2qhc; 2rkf; 2rkg; 3ogq; Lopinavir [USAN:USP:INN:BAN]; AIDS032937; (2S)-N-((1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; (2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; (2S)-N-{(2S,4S,5S)-5-[2-(2,6-Dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl}-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; Lopinavir & PLGA; Lopinavir (Standard); Kaletra (LPV+RTV); 2o4s; 2q5k; 4l1a; LOPINAVIR [INN]; LOPINAVIR [JAN]; LOPINAVIR [MI]; LOPINAVIR [USAN]; LOPINAVIR [VANDF]; Lopinavir (ABT-378); CHEMBL729; Epitope ID:231715; LOPINAVIR [MART.]; LPV & AAG; LOPINAVIR [USP-RS]; LOPINAVIR [WHO-DD]; LOPINAVIR [WHO-IP]; Lopinavir (JAN/USP/INN); SCHEMBL21775; LOPINAVIR [EMA EPAR]; MLS003915624; MLS004774152; MLS006011206; ABT-378; LOPINAVIR; Lopinavir - Bio-X trade mark; orb1307985; LOPINAVIR [ORANGE BOOK]; LOPINAVIR [EP MONOGRAPH]; GTPL11504; LOPINAVIR [USP MONOGRAPH]; KALETRA COMPONENT LOPINAVIR; KJHKTHWMRKYKJE-SUGCFTRWSA-N; GLXC-02734; LOPINAVIRUM [WHO-IP LATIN]; (2s)-n-[(2s,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; EX-A4008; MSK10437; Tox21_112204; BDBM50180655; EBC-06069; HB7108; HY-14588R; Lopinavir & alpha1-acid glycoprotein; Lopinavir for system suitability CRS; s1380; Lopinavir for peak identification CRS; AKOS025243115; Tox21_112204_1; CCG-270285; CS-2077; DB01601; FL16558; KS-1436; Lopinavir 100 microg/mL in Acetonitrile; NCGC00164576-01; NCGC00164576-03; NCGC00164576-04; BL164636; HY-14588; SY073885; L0377; L5862; NS00008581; SW219767-1; T1623; D01425; SBI-0654097.0001; AB01274785-01; AB01274785_02; EN300-7402887; Q422585; SR-01000931910; SR-01000931910-2; A-1573780; BRD-K99451608-001-02-4; BRD-K99451608-001-07-3; Z2235801862; Lopinavir Working Standard (Secondary Reference Standard); (?-S)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-?-(1-methylethyl)-; (|_S)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-|_-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; (|AS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-|A-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-DIMETHYLPHENOXY)ACETYL)AMINO)-3-HYDROXY-5-PHENYL-1-(PHENYLMETHYL)PENTYL)TETRAHYDRO-.ALPHA.-(1-METHYLETHYL)-2-OXO-1(2H)-PYRIMIDINEACETAMIDE; (2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-.alpha.-(1-methylethyl)-2-oxo-, (aS)-; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI); 1(2H)-pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)-; 1(2H)-Pyrimidineacetamide, N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, [1S-[1R*(R*),3R*,4R*]]-別名